TOKYO - Japanese pharmaceutical company Daiichi Sankyo Co. will receive payments totaling up to $22 billion from U.S. counterpart Merck & Co. in a tie-up deal covering the development and commercialization of three cancer therapies, the two firms said Friday.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
